Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients

Bone Marrow Transplantation

Volumn 24, Issue 9, 1999, Pages 971-979

  Benedetti, G ^a,b   Patoia, L ^a   Giglietti, A ^a   Alessio, M ^a   Pelicci, P G ^a   Grignani, F ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Ist di Med Int e Sci Oncologiche   (Italy)

Author keywords

Breast cancer; CD34+; High dose; Melphalan; Platelets; Thrombocytopenia

Indexed keywords

CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; MELPHALAN; METHOTREXATE; MYELOABLATIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; ADVANCED CANCER; APHERESIS; ARTICLE; BLOOD TRANSFUSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CLONOGENIC ASSAY; CYTOFLUOROMETRY; ERYTHROCYTE CONCENTRATE; FEMALE; HUMAN; LEUKAPHERESIS; LEUKOCYTE COUNT; PRIORITY JOURNAL; REGRESSION ANALYSIS; STEM CELL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 0032714359     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702008     Document Type: Article

References (35)

1. Peters WP, Shpall EJ, Jones RB et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 9: 1368-1376.
2. Bitran JD, Samuels B, Klein L et al. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. Bone Marrow Transplant 1996; 2: 157-162.
3. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood 1997; 89: 2233-2258.
4. Haas R, Mohle R, Fruhauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-3794.
5. Kotasek D, Shepherd KM, Sage RE et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9: 11-17.
6. Fukuda M, Kojima S, Matsumoto K, Matsuyama T. Autotransplantation of peripheral blood stem cells mobilized by chemotherapy and recombinant human granulocyte colony-stimulating factor in childhood neuroblastoma and non-Hodgkin's lymphoma. Br J Haematol 1992; 80: 327-331.
7. Passos-Coelho JL, Braine HG, Davis JM et al. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization. J Clin Oncol 1995; 3: 705-714.
8. Ho AD, Gluck S, Germond C et al. Optimal timing for collections of blood progenitor cells following induction chemotherapy and granulocyte-macrophage colony-stimulating factor for autologous transplantation in advanced breast cancer. Leukemia 1993; 11: 738-746.
9. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
10. Bender JG, To LB, Williams S, Schwartzberg LS. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992; 1: 329-341.
11. Siena S, Bregni M, Brando B et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991; 77: 400-409.
12. Sheridan WP, Begley CG, Juttner CA et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640-644.
13. Klumpp TR, Mangan KF, Goldberg SL et al. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 1995; 6: 1323-1327.
14. Patoia L, Giglietti A, Benedetti G et al. Phase I-II study of sequential high-dose chemotheraphy (SHDCT) for metastatic breast cancer (MCB) and resectable breast cancer with more than 4 axillary positive nodes (RBC). Ann Oncol 1996; 7 (Suppl. 5): 23.
15. Tarella C, Benedetti G, Caracciolo D et al. Both early and committed haemopoietic progenitors are more frequent in peripheral blood than in bone marrow during mobilization induced by high-dose chemotherapy + G-CSF. Br J Haematol 1995; 3: 535-543.
16. To LB, Roberts MM, Haylock DN et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 4: 277-284.
17. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 10: 2547-2555.
18. Antman K, Corringham R, de Vries E et al. Dose intensive therapy in breast cancer. Bone Marrow Transplant 1992; 10: 67-73.
19. Pettengell R, Testa NG, Swindell R et al. Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma. Blood 1993; 82: 2239-2248.
20. Grigg AP, Roberts AW, Raunow H et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 1995; 86: 4437-4445.
21. + cells in apheresis products from patients mobilized for peripheral blood progenitors with different regimens. Bone Marrow Transplant 1994; 4: 479-485.
22. Brugger W, Bross KJ, Glatt M et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636-640.
23. Passos-Coelho JL, Ross AA, Kahn DJ et al. Similar breast cancer cell contamination of single-day peripheral-blood progenitor-cell collections obtained after priming with hematopoietic growth factor alone or after cyclophosphamide followed by growth factor. J Clin Oncol 1996; 9: 2569-2575.
24. Weaver CH, Moss T, Schwartzberg LS et al. High-dose chemotherapy in patients with breast cancer: evaluation of infusing peripheral blood stem cells containing occult tumor cells. Bone Marrow Transplant 1998; 21: 1117-1124.
25. + cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1997; 19: 303-310.
26. + cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998; 91: 3148-3155.
27. Ayash LJ, Elias A, Wheeler C et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 1994; 1: 37-44.
28. Samuels BL, Bitran JD. High-dose intravenous melphalan: a review. J Clin Oncol 1995; 7: 1786-1799.
29. Vesole DH, Barlogie B, Jagannath S et al. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood 1994; 84: 950-956.
30. + selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer. Blood 1997; 89: 1521-1528.
31. Dyson PG, Jackson KA, McClure BJ et al. Increased levels of megakaryocyte progenitors in peripheral blood mobilised by chemotherapy and/or haemopoietic growth factor protocols. Bone Marrow Transplant 1996; 4: 705-712.
32. + cells best predict platelet recovery after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1998; 21: 1217-1222.
33. Bertolini F, Battaglia M, Pedrazzoli P et al. Megakaryocytic progenitors can be generated ex vivo and safely administered to autologous peripheral blood progenitor cell transplant recipients. Blood 1997; 89: 2679-2688.
34. Bensinger WI, Longin K, Appelbaum F et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825-831.
35. Wallace EL, Churchill WH, Surgenor DM et al. Collection and transfusion of blood and blood components in the United States, 1992. Transfusion 1995; 35: 802-812.